NanoCor Therapeutics

	Intellectual Property NanoCor possesses a mature and vast portfolio of intellectual property rights required for cardiovascular therapeutics. NanoCor’s intellectual property portfolio has resulted from the scientific work of Professor Richard Jude Samulski, Director of Gene Therapy at the University of North Carolina at Chapel Hill, Professor Evangelia Kranias, Director of Cardiovascular Biology at the University of Cincinnati, and Professor Roger Hajjar at Mount Sinai School of Medicine. NanoCor has world-wide, exclusive rights, through an exclusive license-agreement with AskBio, to the BNP™ delivery platform and Self-Complementary Vector Technology for cardiovascular purposes. Both technologies are based on rAAV. NanoCor has secured exclusive rights to a gene, protein Phosphatase-1 Inhibitor-1 (I-1) and a truncated form thereof (I-1c), and other potential product candidates. NanoCor has a proprietary patented gene expression regulation system, and has access to other systems for gene regulation in the heart. In the event that devices such as catheters are used to assist in the delivery of the therapeutic, NanoCor has a patent for the drying down of BNPs™ (as well as AAV and other viruses) onto such support matrices.
				NanoCor Products
				Carfostin™ Overview Product Pipeline Technology Intellectual Property . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
				Contact Us
				870 Martin Luther King Jr. Blvd. Chapel Hill, NC 27514 +1-919-636-9506 blake@nanocorthx.com . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

NanoCor Therapeutics, Inc. is engaged in the development of novel therapeutics for the treatment of various cardiovascular diseases at the molecular level. NanoCor’s lead therapeutic is Carfostin™, an intracellular protein therapeutic for the treatment of Chronic Heart Failure (CHF). Carfostin™ is comprised of the delivery of a therapeutic gene, protein Phosphatase-1 Inhibitor-1 (I-1) with the use of Biological NanoParticles (BNPs™) and the Self-Complementary Vector Technology. This novel approach, which represents an important adjunct to existing therapies, will provide a minimal-invasive treatment for these patients and advance the current standard of care.